Key facts
- This page summarizes Jack Zamora's Form 3 filing for Vitro Biopharma, Inc..
- 0 reported transactions and 8 derivative rows are listed below.
- Accepted by SEC: 17 Nov 2022, 11:45.
Jack Zamora - 11 Nov 2022 Form 3 Insider Report for Vitro Biopharma, Inc.
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- N/A
- Reported as of
- 11 Nov 2022
- Net transaction value
- $0
- Reporting owner signature
- /s/ Jack Zamora
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Jack Zamora filed Form 3 for Vitro Biopharma, Inc. on 17 Nov 2022.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
No ticker
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 34,177,462
- Date
- 11 Nov 2022
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
No ticker
holding
Derivative
Employee Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 11 Nov 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 666,000
- Exercise price
- $0.2900
- Footnotes
- F1
No ticker
holding
Derivative
Employee Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 11 Nov 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,000,000
- Exercise price
- $0.5000
No ticker
holding
Derivative
Warrant (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 11 Nov 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 250,000
- Exercise price
- $0.5000
No ticker
holding
Derivative
Warrant (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 11 Nov 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 250,000
- Exercise price
- $1.00
No ticker
holding
Derivative
Warrant (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 11 Nov 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 180,000
- Exercise price
- $0.5000
No ticker
holding
Derivative
Warrant (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 11 Nov 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 180,000
- Exercise price
- $1.00
No ticker
holding
Derivative
Warrant (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 11 Nov 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 172,929
- Exercise price
- $0.5000
No ticker
holding
Derivative
Warrant (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 11 Nov 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 172,929
- Exercise price
- $1.00
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The option became exercisable as to (i) 333,000 shares on April 9, 2021 and (ii) 333,000 shares on April 9, 2022.